Диагностика и лечение гепатита. Рекомендации Американской гепатологической ассоциации
 

Вернуться к вопросам

 

Библиография

1. Eddy DM. Clinical decision making: from theory to practice. Benefit language: criteria that will improve quality while reducing costs. JAMA 1996; 275:650-657.
2. American Gastroenterological Association. Policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108:925-926.
3. Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE Jr, Sweet RL, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994; 18:421. 
4. Woolf SH, Sox HC Jr. The Expert Panel on Preventive Services: continuing the work of the U.S. Preventive Services Task Force. Am J Prev Med 1991; 7:326-330.
5. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States , 1988 through 1994. N Engl J Med 1999; 341:556-562.
6. Kim WR. The burden of hepatitis C in the United States . Hepatology 2002; 36(suppl 1):S30-S34.
7. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36(suppl 1):S93-S98.
8. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovi-rus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-1690.
9. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C sero-conversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995; 23:273-277. 
10. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Re-comm Rep 1998; 47(RR-19):1-39.
11. Jonas MM. Children with hepatitis C. Hepatology 2002; 36(suppl 1): S173-S178.
12. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36(suppl 1):S99 -S105.
13. Mele A, Corona R, Tosti ME, Palumbo F, Moiraghi A, NovacoF,GalantiC,etal. Beauty treatments and riskofpa-renterally transmitted hepatitis: results from the hepatitis surveillance system in Italy. Scand J Infect Dis 1995; 27:441-444.
14. Sun DX, Zhang FG, Geng YQ, Xi DS, Hepatitis C transmission by cosmetic tattooing in women. Lancet 1996; 347:541.
15. Tumminelli F, Marcellin P, Rizzo S, Barbera S, Corvino G, Furia P, Benhamou JP, et al. Shaving as potential source of hepatitis C virus infection. Lancet 1995; 345:658.
16. Kiyosawa K, Tanaka E, Sodeyama T, Yoshizawa K, Yabu K, Furuta K, Imai H, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology 1994; 106:1596-1602.
17. Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995; 15:15-32.
18. Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, BzowejN,Wright TL. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 2001; 34:1200-1205.
19. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691-1696.
20. Balasekaran R, Bulterys M, Jamal MM, Quinn PG, Johnston DE, Skipper B, Chaturvedi S, et al. A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. Am J Gastroenterol 1999; 94: 1341-1346.
21. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
22. Carithers RL Jr, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Semin Liver Dis 2000; 20:159-171.
23. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(suppl 1):S65-S73.
24. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27:1700-1702.
25. Hoofnagle JH. Course and outcome of hepatitis C. Hepa-tology 2002; 36(suppl 1):S21-S29.
26. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325:98-104.
27. Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo
F, Cariani E. Hepatitis C virus RNA and antibody responsein the clinical course of acute hepatitis C virus infection. He-patology 1992; 16:877-881.
28. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gast-roenterology 2003; 122:1554-1568.
29. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCVRNA. WHO Collaborative Study Group. Vox Sang 1999; 76:149-158.
30. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31(suppl 1):54-60.
31. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterfe-ron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
32. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos
G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEngl J Med 2002; 347:975-982.
33. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferon alfa-2a (40 kilodaltons) and ribovirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
34. Ansaldi F, Torre F, Bruzzone BM, Picciotto A, Crovari P, Icardi G. Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. J Med Virol 2001; 63:17-21.
35. Ross RS, Viazov SO, Holtzer CD, Beyou A, Monnet A, Mazure C, Roggendorf M. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol 2000; 38: 3581-3584.
36. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maer-tens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34:2259-2266.
37. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7:196-202.
38. Nolte FS, Green AM, Fiebelkorn KR, Caliendo AM, Stur-chio C, Grunwald A, Healy M. Clinical evaluation of two methods for genotyping hepatitis C virus based onanalysis of the 5' noncoding region. J Clin Microbiol 2003; 41:1558-1564.
39. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, et al. Sampling error and intra-observer variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618. 
40. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334-1340.
41. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, Pol S. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32:904-909.
42. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36(suppl 1):S47-S56.
43. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
44. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gu-dat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
45. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(suppl 1):122S-127S.
46. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, IdeoG,Bain V, etal. Randomised trial ofinterferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis In-terventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
47. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ, Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
48. Garcia G, Keeffe EB. Liver biopsy in chronic hepatitis C: routine or selective. Am J Gastroenterol 2001; 96:3053-3055.
49. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C.Hepatology 2002; 36(suppl 1):S57-S64.
50. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133:665-675.
51. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36(pt 1):973-977.
52. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminases. J Hepatol 2003; 38:511-517.
53. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996; 8:324-328.
54. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36(suppl 1):S1-S2.
55. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, AlmasioP, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27:201-205.
56. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
57. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832.
58. Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, and Seeff LB. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120-124.
59. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, et al. Impact of pegylated inter-feron alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitisC.Gastroenterology 2002; 122:1303-1313.
60. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, et al. Efficacy and safety of pe-gylated (40-kd) interferon alpha-2a compared with interfe-ron alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-438.
61. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interven-tional Therapy Group. Gastroenterology 2000; 119:1317-1323.
62. Theodore D, Shiffman ML, Sterling RK, Bruno CJ, Wein-stein J, Crippin JS, Garcia G, et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003; 48: 140-145.
63. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
64. Jacobsen IM, Ahmed F, Russo MW, Brown RS, Lebovics E, Min A, Esposito S, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in non-responders to interferon mono-therapy or combination therapy and in combination therapy relapsers: final results [Abstract]. Gastroenterology 2003; 124:A540.
65. Shiffmann ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, et al. Peginterferon al-fa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology, 2004 (in press)
66. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-1499.
67. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P,Albrecht J. Impact of interferon al-fa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:1131-1137.
68. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, NakajimaS,ShiomiS,etal. Randomised trialofeffects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
69. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131:174-181.
70. Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Vila-domiu L, Muniz E, Martin-Vega C, et al. High rate of infec-tivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115:443-449.
71. Prieto M, Olaso V, Verdu C, Cordoba J, Gisbert C, Rayon M, Carrasco D, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22:413-417.
72. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123:330-337.
73. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 2000; 46:2027-2049.
74. Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E, Balart L. Chronic hepatitis C with normal ami-notransferase levels: a clinical histologic study. Am J Gastro-enterol 1997; 92:1788-1792.
75. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V,Levy S, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-1005.
76. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, Vlahov D, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. He-patology 2002; 35:1247-1255.
77. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P,Ruol A.Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340:697-698.
78. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118:760-764.
79. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26(suppl 1):133S-136S.
80. Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics 1998; 101(part 1):481-485.
81. Bortolotti F, Resti M, Giacchino R, Crivellaro C, Zancan L, Azzari C, Gussetti N, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr 1998; 133:378-381.
82. Hsu SC, Chang MH, Chen DS, Hsu HC, Lee CY. Non-A, non-B hepatitis in children: a clinical, histologic, and sero-logic study. J Med Virol 1991; 35:1-6.
83. Bortolotti F, Vajro P, Cadrobbi P, Lepore L, Zancan L, Barbera C, Crivellaro C, et al. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992; 15:73-76.
84. Bortolotti F, Jara P, Diaz C, Vajro P, Hierro L, Giacchino R,delaVegaA, etal. Posttransfusion and community-acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994; 18:279-283.
85. Jonas MM, Ott MJ, Nelson SP, Badizadegan K, Perez-Atayde AR. Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J 1998; 17:241-246.
86. Bortolotti F, Resti M, Giacchino R, Azzari C, Gussetti N, Crivellaro C, Barbera C, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1997; 130:990-993.
87. Kage M, Fujisawa T, Shiraki K, Tanaka T, Kimura A, Shi-mamatsu K, Nakashima E, et al. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 1997; 26:771-775.
88. Badizadegan K, Jonas MM, Ott MJ, Nelson SP, Perez-Atayde AR. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28: 1416-1423.
89. Guido M, Rugge M, Jara P, Hierro L, Giacchino R,Larra-uri J, Zancan L, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998; 115:1525-1529.
90. Fujisawa T, Inui A, Ohkawa T, Komatsu H, Miyakawa Y, Onoue M. Response to interferon therapy in children with chronic hepatitis C. J Pediatr 1995; 127:660-662.
91. Bortolotti F, Giacchino R, Vajro P, Barbera C, Crivellaro C, Alberti A, Nebbia G, et al. Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology 1995; 22:1623-1627.
92. Marcellini M, Kondili LA, Comparcola D, Spada E, Sar-torelli MR, Palumbo M, Rapicetta M. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. Pediatr Infect Dis J 1997; 16: 1049-1053.
93. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, Malizia R, et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood 1997; 90:2207-2212.
94. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34:52-58.
95. Comanor L, Minor J, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001; 8:139-147.
96. Gottrand F, Michaud L, Guimber D, Ategbo S, Dubar G, Turck D, Farriaux JP. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996; 155:1031-1034.
97. Bunn S, Kelly D, Murray KF, Shelton M, Olson A, Mieli-Vergani G, Zambas D, et al. Safety, efficacy and pharma-cokinetics of interferonalfa-2b and ribavirin in children with chronic hepatitis C [Abstract]. Hepatology 2000; 32: 350A.
98. Gonzalez-Peralta R, Haber BA, Jonas M, Martin S, Lang T, Geffner M, Albrecht J. Interferon-alfa 2b in combination with ribavirin for the treatment of chronic hepatitis C in children [Abstract]. Hepatology 2002; 36(pt 2): 311A.
99. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
100. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
101. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
102. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-247.
103. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001; 26:340-344.
104. Marcellin P, Martinot-Peignoux M, Elias A, Branger M, Courtois F, Level R, Erlinger S, et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-serone-gative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 1994; 170: 433-435.
105. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36(suppl 1): S201-S209.
106. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a me-ta-analysis. Clin Infect Dis 2001; 33:562-569.
107. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
108.Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, Martinez-Odriozola P, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585-591.
109. Soriano V, Bravo R, Garcia-Samaniego J, Castilla J, Gonzalez J, Castro A, Llibre JM. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group. AIDS 1997; 11:400-401.
110. Chung R, Anderson J, Volberding P, Robbins G, Liu T, Sherman K, Peters M, Koziel M, et al. A Randomized, Controlled Trial of PEG-Interferonalfa-2a plus Ribavirin vs Interferon-alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-co-infected Persons: Follow-up Results of ACTG A5071. Abstract 110. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004. San Francisco, CA.
111. Perronne C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, Morand P, et al. Final results of ANRS HC02-RIBAVIC: A Randomized Controlled Trial of Pegylated-Interferon-alfa-2b plus Ribavirin vs Interferonalfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis C in HIV Co-Infected Patients. Abstract 117LB. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004. San Francisco, CA.
112. Torriani FJ, Rockstroh J, Rodriguez-Torres M, Lissen E, Gonzalez J, Lazzarin A, Carosi G, et al. Final Results of APRICOT: A Randomized, Partially Blinded, International Trial Evaluating Peginterferon-alfa-2a. Ribavirin vs In-terferon-alfa-2a. Ribavirin in the Treatment of HCV in HIV/HCV Co-infection. Abstract 112. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004. San Francisco, CA.
113. Moore RD, Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999; 29:44-49.
114. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231-1236.
115. Lafeuillade A, Hittinger G, Chadapaud S. Increased mi-tochondrial toxicity with ribavirin in HIV/HCV coinfecti-on. Lancet 2001; 357:280-281.
116. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silber-mann B,SogniP.Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1803-1804.
117. Squibb BM. Videx-EC Patient Information. 2003. Available at: www. videx.com.
118. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-1379.
119. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694-697.
120. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine MD. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14:1857-1858.
121. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38-47.
122. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B,Walker R, et al. Interferon-alphain patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112:805-811.
123. Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med 2003; 348:2279-2281.
124. Fox R, Hepatitis C virus outside the liver. Current Hepatitis Reports 2003; 2:117-124.
125. Agnello V, Chung RT, and Kaplan LM. A role for hepatitis C virus infectionintypeII cryoglobulinemia.NEnglJMed 1992; 327:1490- 1495.
126. Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States-1994. ASAIO J 1997; 43:108-119.
127. Huang CC. Hepatitis in patients with end-stage renal disease. J Gastroenterol Hepatol 1997; 12:S236-S241.
128. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32:629-634.
129. Djordjevic V, Kostic S, Stefanovic V. Treatment of chronic hepatitis C with interferon alpha in patients on maintenance hemodialysis. Nephron 1998; 79:229-231.
130. Morales JM, Munoz MA, Castellano G, Colina F, Fuertes A, AndresA, Campo C, et al. Impactof hepatitis C in long-functioning renal transplants: a clinicopathological follow-up. Transplant Proc 1993; 25(part 2):1450-1453.
131. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66:471-476.
132. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
133. Ynares C, Johnson HK, KerlinT,Crowe D, MacDonell R, Richie R. Impact of pretransplant hepatitis C antibody status upon long-term patient and renal allograft survival-a 5-and 10-year follow-up. Transplant Proc 1993; 25(part 2): 1466-1468.
134. Ferri C, Marzo E, Longombardo G, La Civita L, Lombar-diniF, GiuggioliD,VanacoreR, etal. Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial. Gut 1993; 34(suppl):S144 -S145.
135. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Si-roni PL, Zilio P, et al. Interferon alfa-2a therapy in cryog-lobulinemia associated with hepatitisCvirus. NEngl JMed 1994; 330:751-756.
136. Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991; 78:3142-3147.
137. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenba-um M, Toubi E, Sabo E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobuli-nemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27:2172-2178.
138. Gordon AC, Edgar JD, Finch RG. Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia. J Infect 1998; 36:229-230.
139. Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T, Furuichi K, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after inter-feron therapy. Am J Kidney Dis 1999; 33:1040-1048.
140. Suzuki T, Yonemura K, Miyaji T, Suzuki H, Takahira R, Fujigaki Y, Fujimoto T, et al. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis. Intern Med 2001; 40:708-712.
141. Meyers CM, Seeff LB, Stehman-Breen O, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42:631-657.
142. Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, Kashiwagi S. Liver damage in he-modialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000; 45:2221-2228.
143. Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, Mills AS, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94:3576-3582.
144. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19(suppl 1):17-24.
145. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16:193-195.
146. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24:701-708.
147. Sulkowski M, Wasserman R, Brooks L, Ball, Gish R. Changes in hemoglobin during interferon alfa 2b plus ribavirin combination therapy for hepatitis C virus infection. J Viral Hepat 2004. In press.
148. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45:1507-1509.
149. Fernandez JL, Rendo P, del Pino N, Viola L. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J Viral Hepat 1997; 4:113-119.
150. Campistol JM, Esforzado N, Martinez J, Rosello L, Vecia-na L, Modol J, Casellas J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre-and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14:2704-2709.
151. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, et al. The tolerance and efficacy of interfe-ron-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16:1017-1023.
152. Tokumoto T, Tanabe K, Ishikawa N, Simizu T, Oshima T, Noguchi S, Gouya N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999; 31: 2887-2889.
153. HuraibS,TanimuD,Romeh SA, QuadriK,AlGhamdiG, Iqbal A, Abdulla A. Interferon-alpha in chronic hepatitis C infection indialysis patients. Am J Kidney Dis 1999; 34:55-60.
154. Everson GT, Trouillot T, Trotter J, Skilbred J, Halprin A, McKinley C, Fey B, et al. Treatment of decompensated cirrhotics with a low-accelerating dose regimen (LADR) of interferon-alfa-2b plus ribavirin: safety and efficacy [Abstract]. Hepatology 2000; 32:308A.
155. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrar-gues G, Fenyves D, Bilodeau M, Leduc R, et al. Lamivudi-ne treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207-210.
156. Yao FY, Bass, NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:301-307.
157. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. In-terferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-1121.
158. Everson GT. Treatment of patients with hepatitis C on the waiting list. Liver Transpl 2003; 9:S90-S94.
159. Crippin JS, McCashland T, Terrault N, Sheiner P, Charl-ton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-355.
160. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
161. Kasper C. Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies. Ann Hematol 2001; 80:319-329.
162. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185(suppl 2):S128-S137. 
163. Itri LM. The useofepoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Semin Oncol 2002; 29(suppl 8):81-87.
164. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(suppl 1):S237-S244.
165. Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interfe-ron-gamma. J Infect Dis 2002; 185:1490-1501.
166. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, Burniat A, et al. Therapeutic use of granulo-cyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10:181-188.
167. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, CombsC, etal. Recurrent and acquired hepatitisC viral infection in liver transplant recipients. Gastroenterology 1992; 103:317-322.
168. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53:1374-1381.
169. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35:666-678.
170. Mancini C, Gaeta A, Lorino G, Filadoro F, Marinucci G, Bachetoni A,PretagostiniR,et al. Alpha interferon therapy in patients with hepatitis infection undergoing organ transplantation. Transplant Proc 1989; 21(pt 2):2429-2430.
171. Chan TM, Lok AS , Cheng IK, Ng IO. Chronic hepatitis C after renal transplantation. Treatment with alpha-interfe-ron. Transplantation 1993; 56:1095-1098.
172. Reddy KR, Fried MW, Dixon R, Martin P, Torres M, Weppler D,Ruiz P, etal. Interferon alfa-2b and ribavirin vs placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multi-center, randomized trial. Gastroenterology 2002; 122:199.
173. Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, Marino IR. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65:82-86.
174. Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, Mor E, et al. The efficacy of prophylactic interfe-ron alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831-838.
175. Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, Baratti D, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997; 29:519-521.
176. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, Pouyet M, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500-504.
177. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, Gish R, et al. A pilot study of interfe-ron alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 1253-1258.
178. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Le-monnier C, Cohard M, et al. Interferon-alpha 2b plus riba-virin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650.
179. Narayanan Menon KV, Poterucha JJ, El-Amin OM, Bur-gart LJ, Kremers WK, Rosen CB, Wiesner RH, etal. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8:623-629.
180. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32(pt 1):852-858.
181. Sheiner PA, Schluger LK, Emre S, Thung SN, Lau JY, Guy SR, Schwartz ME, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3:130-136.
182. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence ofviremia and the importanceoflong-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908-914.
183. Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology 2002; 36(suppl 1):S195-S200.
184. Poynard T, Regimbeau C, Myers RP, Thevenot T, Leroy V, MathurinP, OpolonP,et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002; 1:CD000369.
185. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allin-ger S, Grunewald K, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996; 41(suppl):81S-85S.
186. Pimstone NR, Powell JS, Kotfila R, Primstone DJ, Davidson L. High dose (780 MU/52 weeks) interferon monothe-rapy is highly effective treatment for acute hepatitis C [abstract]. Gastroenterology 2000; 118:A960.
187. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, et al. Treatment of acute hepatitis C with interferon alfa2b. N Engl J Med 2001; 345:1452-1457.
188. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88.
189. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345:211-215.
190. Gossop M, Marsden J, Stewart D, Rolfe A. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2000; 60:275-286.
191. Geber WF, Lefkowitz SS, Hung CY. Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum inter-feron level in response to viral infection. Arch Int Pharma-codyn Ther 1975; 214:322-327.
192. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-123.
193. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, et al. Adherence and mental side effects during hepatitis C treatment with inter-feron alfa and ribavirin in psychiatric risk groups. Hepato-logy 2003; 37:443-451. 
194. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-1483.
195. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135-140.
196. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, Lanford RE. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33:1479-1487.
197. Asselah, T, Vidaud D, Doloy A, Boyer N, Martinot M, Vi-daud M, Valla D, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003; 52:900-902.
198. Golub ET, LatkaM, Hagan H, HavensJ, HudsonS, Kapa-dia F, Campbell JV, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck's depression inventory. J Urban Health 2004 (in press).
199. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001; 61:211-215.
200. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-193.
201. Wiley TE, McCarthy M, Breide L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28:805-809.
202. Corrao G, Arico S. Independent and combined action of hepatitis Cvirus infections and alcohol consumption on the risk of symptomatic cirrhosis. Hepatology 1998; 27:914-917.
203. Bellantani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, Masutti F, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44:874-880.
204. Noda K, Yoshihara H, Suzuki Y, Yamada Y, Kasahari A, Hayashi N, Fusamoto H, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma-its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res 1996; 20(suppl):94A-100A.
205. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinoy-PeignouxM,DegottC, etal. Effect ofalcohol consumption on serum hepatitis C virus RNA and histolo-gical lesions in chronic hepatitis C. Hepatology 1998; 27: 1717-1722.
206. Romero-Gomez M, Grande L, Nogales MC, Fernandez, M, Chavez M, Castro M. Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 2001; 33:698-702.
207. Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, Dhillon AP, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2000; 9:235-241.
208. Hourigan LF, MacDonald GA, Purdie D, Whitehall VH, Shorthouse D, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29:1215-1219.
209. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97:2408-2414.
210. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989; 110:838-839.
211. Vento S, Garofano T, Renzini C, Cairelli F, Casali F, Ghi-ronzi G, Ferraro T, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286-290. 
212. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48(RR-12):1-37.
213. Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Independent and additive effect modification of hepatitis B and C virus infection on the development of chronic hepatitis. J Hepatol 1996; 24:271-276.

Вернуться к вопросам

Реклама: